Biosante Pharmaceuticals Inc., of Lincolnshire, Ill. said it received a U.S. patent covering its method for selectively isolating biologically active therapeutic proteins from transgenic milk.
Cellular Genomics Inc., of Branford, Conn., said it received U.S. Patent No. 6,242,205. It covers a method of detecting integral membrane protein-protein interactions.
Genomic Solutions Inc., of Ann Arbor, Mich., said it received U.S. Patent No. 6,238,910 titled ¿Thermal and Fluidic Cycling Device For Nucleic Acid Hybridization.¿ It covers the automated hybridization of DNA microarrays.
Immunicon Corp., of Huntingdon Valley, Pa., said it received U.S. Patent No. 6,228,624 titled ¿Methods to Select and Transfect Cell Subpopulations.¿ It covers claims related to a method of targeting, transfecting and separating cells in gene therapy applications.
Nanogen Inc., of San Diego, said it received U.S. Patent No. 6,238,624 titled ¿Methods for Electronic Transport in Molecular Biological Analysis and Diagnostics.¿ It covers methods for electronically transporting charged entities and for array replication.
Nastech Pharmaceutical Co., of Hauppauge, N.Y., said it received U.S. Patent No. 6,225,343. It covers compositions and methods comprising morphine gluconate.
Progen Industries Ltd., of Brisbane, Australia, said it received U.S. Patent No. 6,242,238 titled ¿Isolated Nucleic Acid Molecule Encoding Mammalian Endoglucuronidase and Uses Thereof.¿ It covers the sequence, expression and use of mammalian heparanase.
StemCells Inc., of Palo Alto, Calif., said it received two U.S. patents covering a method to separate neural stem cells for growth in culture and a unique murine model for identifying stem-progenitor cells for the pancreas and liver.
Targeted Genetics Corp., of Seattle, said it received U.S. Patent Nos. 6,238,914; 6,183,993; and 6,190,887. They cover the use of nonmammalian viruses as vectors for gene therapy.
Vasogen Inc., of Toronto, said it received notice of allowance for a U.S. patent titled ¿Method for Preventing and Reversing Atherosclerosis.¿ It covers Vasogen¿s immune modulation therapy in the prevention and reduction of atherosclerosis.